CONCLUSIONS: CBPR can help create meaningful resources to increase visibility, awareness, and hope in historically underrepresented communities. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Ms. Chandra has stock in Abbvie. Ms. Chandra has received research support from New York Academy of Medicine. Ms. Chandra has received personal compensation in the range of $10,000-$49,999 for serving as a Postbaccalaureate...

CONCLUSIONS: This qualitative and quantitative hypothesis-generating data is the start to understanding the challenges faced by community neuro-oncology providers. These results will guide future studies and recommendations aimed toward better supporting them and their patients. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Lu-Emerson has received personal compensation in the range of $500-$4,999 for serving as...

CONCLUSIONS: SmartRehab is a feasible and effective telerehabilitation platform for stroke recovery, with high user satisfaction. Significant motor function improvements were observed. Addressing technological barriers may enhance adherence and outcome Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Saleh Velez has nothing to disclose. Mr. Yeung has stock in ReMobility Limited. The institution of Mr. Yeung has...

CONCLUSIONS: Frexalimab continues to show favorable safety and sustained reduction in disease activity in pwRMS through W96, supporting its further development in phase 3 trials as a potential high-efficacy, non-lymphocyte-depleting therapy. Disclosure: Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck....

CONCLUSIONS: Lowering intracranial pressure in the setting of IIH is a novel etiology for RCVS that has not been described before. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Mardini has nothing to disclose. Shivaansh Aggarwal, MD has nothing to disclose. Dr. Singh has nothing to disclose. Dr. Al-Awwad has nothing to disclose.